High-Mobility Group Box 1 Protein (HMGB1) as a novel diagnostic tool for toxic epidermal necrolysis and Stevens-Johnson syndrome

Archives of Dermatology

Volumn 147, Issue 9, 2011, Pages 1110-1112

  Nakajima, Saeko ^a   Watanabe, Hideaki ^b   Tohyama, Mikiko ^c   Sugita, Kazunari ^d   Iijima, Masafumi ^b   Hashimoto, Koji ^c   Tokura, Yoshiki ^d   Nishimura, Youichi ^e   Doi, Hiromi ^a   Tanioka, Miki ^a   Miyachi, Yoshiki ^a   Kabashima, Kenji ^a  

^a KYOTO UNIVERSITY   (Japan)

^b SHOWA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^e Nishimura Dermatology Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIBIOTIC AGENT; CARBAMAZEPINE; CEFDITOREN PIVOXIL; CELECOXIB; CYANAMIDE; DICLOFENAC; DOCETAXEL; HIGH MOBILITY GROUP B1 PROTEIN; IMATINIB; LANSOPRAZOLE; LOSARTAN POTASSIUM; MAGNESIUM OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOBARBITAL; PHENYTOIN; SERRATIOPEPTIDASE; TRANEXAMIC ACID; VALSARTAN;

ADULT; ARTICLE; BLOOD SAMPLING; DIFFERENTIAL DIAGNOSIS; DRUG ERUPTION; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA MULTIFORME; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MEASLES LIKE RASH; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPIDERMAL NECROLYSIS, TOXIC; HMGB1 PROTEIN; HUMANS; MALE; MIDDLE AGED; SKIN; STEVENS-JOHNSON SYNDROME;

EID: 80053076099     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2011.239     Document Type: Article

References (7)

1. Borchers AT, Lee JL, Naguwa SM, Cheema GS, Gershwin ME. Stevens- Johnson syndrome and toxic epidermal necrolysis. Autoimmun Rev. 2008;7(8):598-605.
2. Bianchi ME, Manfredi AA. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev. 2007;220:35-46. (Pubitemid 350045574)
3. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol. 2010;28:367-388.
4. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens- Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol. 2002;138(8):1019-1024. (Pubitemid 34875605)
5. Chung WH, Hung SI, Yang JY, et al. Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. Nat Med. 2008;14(12):1343-1350.
6. Abe R, Yoshioka N, Murata J, Fujita Y, Shimizu H. Granulysin as a marker for early diagnosis of the Stevens-Johnson syndrome. Ann Intern Med. 2009;151(7):514-515.
7. Murata J, Abe R, Shimizu H. Increased soluble Fas ligand levels in patients with Stevens-Johnson syndrome and toxic epidermal necrolysis preceding skin detachment. J Allergy Clin Immunol. 2008;122(5):992-1000.